This Month in Psychopharmacology

THIS MONTH IN
PSYCHOPHARMACOLOGY

A Beacon of Hope in The Storm of Mental Illness: An Update On Suicide Risk and Prevention Awareness with Dr. Christine Moutier
May 26, 2020

With the recent COVID-19 pandemic, mental health concerns are on the rise. What do we know about the relationship between suicide risk and previous pandemics or natural disasters? What are some protective factors against suicide, and how can we capitalize on these, especially during this challenging time? We recently sat down with the Chief Medical Officer of the American Foundation for Suicide Prevention (AFSP), Dr. Christine Moutier to discuss these questions and more in a recent NEI Podcast episode.

Use of Benzodiazepines or Z-drugs Not Associated With Subsequent Dementia
May 19, 2020

Benzodiazepines and Z-drugs are indicated for treatment of affective disorders and insomnia. Due to cognitive side effects of these treatments, their use has been investigated as risk factors for dementia. However, previous investigations have yielded conflicting results...

Continue reading (Members only)

Incidence and Lethality of Suicidal Acts from 2006 to 2015
May 15, 2020

A recent cross-sectional study was conducted to evaluate trends in the incidence rates and lethality of suicidal acts from 2006 to 2015 among people aged 10 to 74 years of age. The study was based on data...

Increased Treatment Admissions Involving Methamphetamine Use
May 11, 2020

Use and abuse of methamphetamines (meth) can have horrible physical and psychiatric consequences; unfortunately, data indicate that meth use/abuse is on the rise. In this study, conducted using data from a national database involving 15,747,334 drug-related treatment admissions, the authors investigated...

Continue reading (Members only)

Impact of COVID-19 on Families and Individuals With Autism
May 7, 2020

During this unprecedented time of social isolation and disruption to normal, everyday activities, nearly every American has been affected in one way or another. However, for those suffering with autism and their caregivers, the...

FDA Cautions Against Hydroxychloroquine or Chloroquine for COVID-19 Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems
May 5, 2020

The U.S. Food and Drug Administration has recently announced warnings against the use of hydroxychloroquine or chloroquine for treating or preventing SARS beta-coronavirus 19 (COVID-19) infection. Hydroxyquinoline is...

Positive Results for a Non-D2 Antipsychotic
May 3, 2020

The mainstay mechanism of action for available conventional and atypical antipsychotics typically involves antagonism or partial agonism of dopamine D2 receptors. However, currently available D2-binding antipsychotics often lack efficacy, especially in terms of negative and cognitive symptoms of schizophrenia, and may increase risk of potentially serious adverse events including motor symptoms and metabolic issues...

Continue reading (Members only)

Alcohol Use and Misuse During the COVID-19 Pandemic: A Potential Public Health Crisis?
April 17, 2020

Some people with addictive disorders may be especially vulnerable to COVID-19 infection and the inadvertent negative consequences of social distancing implemented specifically to curtail the rate of infection...

A Randomized Proof-of-Mechanism Trial Applying the ‘Fast-Fail’ Approach to Evaluating κ-Opioid Antagonism as a Treatment for Anhedonia
April 15, 2020

The first Fast-Fail trial funded by the National Institute of Mental Health has identified a target for treating anhedonia. The Fast-Fail Trials initiative aims to improve early phase drug development...

Continue reading (Members only)

Treating Mental Health Using Telepsychiatry with Michele Novella, PMHNP-BC
April 13, 2020

We recently sat down with psychiatric nurse practitioner, Michele Novella in our most recent NEI Podcast episode, “Treating Mental Health Using Telepsychiatry with Michele Novella” to discuss this timely and important information for your practice...

Top of Page